Storage Buffer | 10mM HEPES pH 7.4, 100mM NaCl |
Storage Temperature | -80ºC |
Shipping Temperature | Dry Ice. Shipping note: Product will be shipped separately from other products purchased in the same order. |
Purification | Ion-exchange Purified |
Cite This Product | Human Recombinant Tau (K18) P301L Mutant Pre-formed Fibrils (StressMarq Biosciences | Victoria, BC CANADA | Catalog# SPR-523) |
Certificate of Analysis | Protein certified > 95% pure via SDS-PAGE and A260/A280 ratio |
Other Relevant Information | Monomer source is SPR-328 |
Alternative Names | Tau PFFs, Tau PFF, Tau protein Pre-formed Fibrils, Tau aggregates, microtubule-associated protein Tau, MAPT, MAP, microtubule-associated protein, Paired Helical Filament-Tau, Phf-Tau, Neurofibrillary Tangle Protein, G Protein Beta1/Gamma2 Subunit-Interacting Factor 1, Isoform 4, tubulin-associated unit |
Research Areas | Alzheimer's Disease, Neurodegeneration, Neuroscience, Tangles & Tau |
Swiss Prot | P10636 |
Scientific Background | Tauopathies are a class of neurodegenerative diseases characterized by the pathological aggregation of tau protein. The K18 fragment, comprising the microtubule-binding repeat domains of tau, is frequently used in experimental models due to its propensity to form fibrillar aggregates. The P301L mutation, located within the repeat domain, has been demonstrated to increase the protein's propensity to aggregate and seed, making it a key variant in modeling tau pathology. Our Tau (K18) P301L Mutant Pre-formed Fibrils are fibrillized without heparin and have been demonstrated to be neurotoxic to primary mouse cortical neurons. |
References |
1.,Peeraer, E., Bottelbergs, A., Van Kolen, K., Stancu, I. C., Vasconcelos, B., Mahieu, M., Duytschaever, H., Ver Donck, L., Torremans, A., Sluydts, E., Van Acker, N., Kemp, J. A., Mercken, M., Brunden, K. R., Trojanowski, J. Q., Dewachter, I., Lee, V. M., & Moechars, D. (2015). Intracerebral injection of preformed synthetic tau fibrils initiates widespread tauopathy and neuronal loss in the brains of tau transgenic mice. Neurobiology of disease, 73, 83–95. https://doi.org/10.1016/j.nbd.2014.08.032 2.,Croft, C. L., Goodwin, M. S., Ryu, D. H., Lessard, C. B., Tejeda, G., Marrero, M., Vause, A. R., Paterno, G., Cruz, P. E., Lewis, J., Giasson, B. I., & Golde, T. E. (2021). Photodynamic studies reveal rapid formation and appreciable turnover of tau inclusions. Acta Neuropathologica, 141, 359–381. https://doi.org/10.1007/s00401-021-02264-9 3.,Zhang, X., Wang, J., Zhang, Z., & Ye, K. (2024). Tau in neurodegenerative diseases: molecular mechanisms, biomarkers, and therapeutic strategies. Translational Neurodegeneration, 13(40). https://doi.org/10.1186/s40035-024-00429-6 |
In vitro seeding activity of Tau (K18) P301L Mutant Pre-Formed Fibrils in a ThT assay. Tau (K18) P301L Mutant Pre-Formed Fibrils (SPR-523) seed fibril formation of Tau (K18) P301L Mutant Pre-Formed Fibrils (SPR-328) over 72 hours. Reactions (100uL) are shaken at 600 rpm in Greiner-Bio 96 Well Non-Binding Cell Culture Microplates, Black (Greiner-Bio Catalog #655900) at 37C in the presence of 25 uM ThT and read with an XPS Microplate Reader set at 450nm ex/485nm em.
Tau (K18) P301L Mutant Pre-Formed Fibrils (average = 49.7%, SD = 9.6, n = 6) demonstrate increased toxicity to primary mouse cortical neurons compared to the Tau (K18) P301L Mutant Monomers (average = 97.9%, SD = 14.9, n = 11). The protein constructs and a control (10 µM Afatinib) were added to the neuron cultures at 12 DIV and toxicity assessed via a CCK-8 assay at 15 DIV.
Reviews
There are no reviews yet.